Proxima

Proxima, based in the US, specializes in leveraging advanced AI technologies for drug discovery, focusing on developing proximity-based therapeutic modalities to address complex challenges in the pharmaceutical industry. Founded in 2019 in New York, Proxima focuses on advanced drug discovery methodologies. The company has pivoted from previous strategies and has secured a total of USD 80 mn in funding through a SEED round led by DCVC, with participation from various investors including AIX Ventures and Alexandria Venture Investments. The most recent deal occurred on January 13, 2026.

Proxima does not operate as a subsidiary and has not been formed through a merger or carve-out. Proxima specializes in advanced AI-driven drug discovery, focusing on the development of proximity-based therapeutic modalities. Its core offerings include technologies designed to enhance data generation for drug discovery, which are pivotal in addressing complex scientific challenges in the pharmaceutical industry. The company has engaged in collaborations with Halda Therapeutics and Blueprint Medicines, indicating a commitment to pioneering next-generation medicines, particularly in the RIPTAC domain.

Proxima's solutions target a diverse client base, including pharmaceutical companies and research institutions across North America and Europe, facilitating the discovery of novel compounds and accelerating the drug development process. Proxima's revenue model is robust, centered around strategic partnerships and research collaborations, exemplified by a significant agreement with Halda Therapeutics with a total potential value exceeding USD 1 bn. The company conducts B2B transactions primarily with pharmaceutical firms and research organizations, providing proprietary platforms and technologies that enhance drug discovery efforts. While specific pricing details for products and services are not disclosed, they are structured around licensing agreements, project-based collaborations, and long-term partnerships, ensuring a steady revenue stream aligned with the success of the therapeutic candidates developed through their technologies.

In January 2026, Proxima raised USD 80 mn in SEED funding led by DCVC, with participation from AIX Ventures, Alexandria Venture Investments, Braidwell, and others. The company plans to utilize this funding to accelerate the development of new drug candidates, expand the range of disease targets it can address, and enhance the data and technology supporting its discovery platform. Proxima is also strategizing to introduce new products designed for the drug discovery market and aims to expand its operations into additional geographic regions across Europe by the end of 2026.